Should I buy or sell Cellebrite DI stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellebrite DI in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLBT shares. View CLBT analyst ratings or view top-rated stocks .

What is Cellebrite DI's stock price target for 2024?

5 Wall Street research analysts have issued 12 month price targets for Cellebrite DI's shares. Their CLBT share price targets range from $9.00 to $16.00. On average, they expect the company's stock price to reach $12.30 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View analysts price targets for CLBT or view top-rated stocks among Wall Street analysts .

How have CLBT shares performed in 2024?

Cellebrite DI's stock was trading at $8.66 at the start of the year. Since then, CLBT shares have increased by 18.8% and is now trading at $10.29. View the best growth stocks for 2024 here .

Are investors shorting Cellebrite DI?

Cellebrite DI saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 2,480,000 shares, a drop of 5.3% from the March 15th total of 2,620,000 shares. Based on an average daily volume of 998,300 shares, the short-interest ratio is currently 2.5 days. Currently, 4.5% of the shares of the stock are short sold. View Cellebrite DI's Short Interest .

When is Cellebrite DI's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024. View our CLBT earnings forecast .

How can I listen to Cellebrite DI's earnings call?

Cellebrite DI will be holding an earnings conference call on Thursday, May 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Cellebrite DI's earnings last quarter?

Cellebrite DI Ltd. (NASDAQ:CLBT) announced its quarterly earnings data on Thursday, February, 15th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. The business had revenue of $93.01 million for the quarter, compared to analyst estimates of $85.43 million. Cellebrite DI had a positive trailing twelve-month return on equity of 173.14% and a negative net margin of 24.94%.

What ETFs hold Cellebrite DI's stock?

ETFs with the largest weight of Cellebrite DI (NASDAQ:CLBT) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL) . Amplify BlueStar Israel Technology ETF (ITEQ) .

What guidance has Cellebrite DI issued on next quarter's earnings?

Cellebrite DI issued an update on its first quarter 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $83.0 million-$88.0 million, compared to the consensus revenue estimate of $84.3 million.

Who are Cellebrite DI's major shareholders?

Cellebrite DI's stock is owned by many different retail and institutional investors. Top institutional shareholders include Counterpoint Mutual Funds LLC (0.03%) and Hennessy Advisors Inc. (0.01%).

How do I buy shares of Cellebrite DI?

Shares of CLBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CLBT

Cellebrite DI (CLBT) Stock Price, News & Analysis

→ IRS Loophole Gives Americans An Escape From Inflation (From Birch Gold) (Ad)

Free CLBT Stock Alerts

$10.34

-0.04 (-0.39%)

(As of 10:09 AM ET)

Compare

Today's Range: $10.28
▼
$10.41
50-Day Range: $9.25
▼
$12.29
52-Week Range: $5.22
▼
$12.50

Volume: 63,671 shs
Average Volume: 950,283 shs
Market Capitalization: $2.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.30

Get Cellebrite DI alerts:

Cellebrite DI MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 19.5% Upside
$12.30 Price Target
Short Interest: Healthy
4.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.86
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 28.13%
From $0.32 to $0.41 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.75 out of 5 stars

Business Services Sector

176th out of 311 stocks

Prepackaged Software Industry

119th out of 193 stocks

2.5

Analyst's Opinion

Consensus Rating
Cellebrite DI has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cellebrite DI has only been the subject of 4 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
4.47% of the float of Cellebrite DI has been sold short.
Short Interest Ratio / Days to Cover
Cellebrite DI has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cellebrite DI has recently decreased by 5.34%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cellebrite DI does not currently pay a dividend.
Dividend Growth
Cellebrite DI does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLBT.

3.3

News and Social Media Coverage

News Sentiment
Cellebrite DI has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Business Services companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Cellebrite DI this week, compared to 2 articles on an average week.
Search Interest
15 people have searched for CLBT on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Cellebrite DI to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cellebrite DI insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.70% of the stock of Cellebrite DI is held by insiders.
Percentage Held by Institutions
45.88% of the stock of Cellebrite DI is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Cellebrite DI are expected to grow by 28.13% in the coming year, from $0.32 to $0.41 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cellebrite DI is -23.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cellebrite DI is -23.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Cellebrite DI has a PEG Ratio of 1.85. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Cellebrite DI has a P/B Ratio of 57.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Birch Gold

IRS Loophole Gives Americans An Escape From Inflation

In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.

Request your info kit on gold now

About Cellebrite DI Stock (NASDAQ:CLBT)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft. It provides Inseyets, a digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations. The company's digital forensics software also offers data extraction, decoding capabilities, workflows, and automation capabilities. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence by automating data analysis and visualization; Smart Search, an open source intelligence tool that automates the collection and review of publicly available online data; and Guardian, a case and evidence management solution. Further, the company offers digital forensic software for enterprises and service providers, including Inseyets for Enterprise, Endpoint Inspector, and Mobile Now; and professional services, such as training and certification services, and other services. It serves federal and state and local agencies. The company was incorporated in 1999 and is headquartered in Petah Tikva, Israel.

CLBT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLBT Stock News Headlines

April 16, 2024 | americanbankingnews.com

Short Interest in Cellebrite DI Ltd. (NASDAQ:CLBT) Drops By 5.3%

April 10, 2024 | globenewswire.com

Cellebrite to Report First-Quarter 2024 Financial Results on May 23, 2024

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 28, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Technology Stocks: Verint Systems (VRNT), Cellebrite DI (CLBT)

March 28, 2024 | finance.yahoo.com

What Does Cellebrite DI Ltd.'s (NASDAQ:CLBT) Share Price Indicate?

March 25, 2024 | globenewswire.com

Cellebrite Hires Marketing Veteran David Gee as Chief Marketing Officer, Ushering in Next Phase of Growth, Scale and Market Leadership

March 21, 2024 | finance.yahoo.com

Cellebrite Files its 2023 Annual Report on Form 20-F

March 21, 2024 | globenewswire.com

Cellebrite Files its 2023 Annual Report on Form 20-F

April 18, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 14, 2024 | finance.yahoo.com

Cellebrite Revolutionizes Data Collection with Ground-breaking SaaS Solution, Integral Part of Company’s Case-to-Closure Platform

March 14, 2024 | globenewswire.com

Cellebrite Revolutionizes Data Collection with Ground-breaking SaaS Solution, Integral Part of Company's Case-to-Closure Platform

March 12, 2024 | globenewswire.com

UPDATE – Cellebrite Announces 2024 Investor Day

March 12, 2024 | globenewswire.com

Cellebrite Announces 2024 Investor Day

March 7, 2024 | globenewswire.com

Cellebrite Launches FedRAMP Authorization Process to Provide Federal Customers with Enhanced Cloud Security

March 7, 2024 | globenewswire.com

Cellebrite Launches FedRAMP Authorization Process to Provide Federal Customers with Enhanced Cloud Security

March 6, 2024 | finanznachrichten.de

Cellebrite DI Ltd: Haim Shani Concludes Tenure at Cellebrite as Company Enters Next Growth Phase

March 6, 2024 | globenewswire.com

Haim Shani Concludes Tenure at Cellebrite as Company Enters Next Growth Phase

February 21, 2024 | investors.com

Cheap Stocks To Buy: Should You Watch These 5 Growth Stocks? Bitcoin Miner Aims At Breakout

February 19, 2024 | msn.com

Cellebrite DI Ltd. (CLBT) Is Up 20.78% in One Week: What You Should Know

February 18, 2024 | finance.yahoo.com

Cellebrite DI Ltd. (NASDAQ:CLBT) Just Reported And Analysts Have Been Lifting Their Price Targets

February 16, 2024 | finance.yahoo.com

Cellebrite DI Ltd. (NASDAQ:CLBT) Q4 2023 Earnings Call Transcript

February 16, 2024 | finance.yahoo.com

private companies who own 48% along with institutions invested in Cellebrite DI Ltd. (NASDAQ:CLBT) saw increase in their holdings value last week

February 15, 2024 | markets.businessinsider.com

William Blair Keeps Their Hold Rating on Cellebrite DI (CLBT)

February 15, 2024 | finanznachrichten.de

Cellebrite DI Ltd: Cellebrite Announces Fourth-Quarter 2023 Results

February 15, 2024 | seekingalpha.com

Cellebrite DI Ltd. 2023 Q4 - Results - Earnings Call Presentation

February 15, 2024 | finance.yahoo.com

Cellebrite (CLBT) Benefitting from Increased Data Volume

February 15, 2024 | finance.yahoo.com

Cellebrite Announces Fourth-Quarter 2023 Results

See More Headlines

Receive CLBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellebrite DI and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/18/2024
Next Earnings (Confirmed): 5/23/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Business Services
Industry: Prepackaged software
Sub-Industry: N/A
Current Symbol: NASDAQ:CLBT
CUSIP: N/A
CIK: 1854587
Web: www.cellebrite.com
Phone: 972-73-394-8000
Fax: 972-3924-7104
Employees: 1,008
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.30
High Stock Price Target: $16.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +18.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 32.44
P/E Growth: 1.85
Net Income: $-81,100,000.00
Net Margins: -24.94%
Pretax Margin: -23.24%
Return on Equity: 173.14%
Return on Assets: 12.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.66
Quick Ratio: 1.62

Sales & Book Value

Annual Sales: $325.11 million
Price / Sales: 6.55
Cash Flow: $0.27 per share
Price / Cash Flow: 38.94
Book Value: $0.18 per share
Price / Book: 57.67

Miscellaneous

Outstanding Shares: 205,300,000
Free Float: 193,595,000
Market Cap: $2.13 billion
Optionable: Optionable
Beta: 1.53

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Yossi Carmil (Age 56)
Founder, CEO & Director
Comp: $1.14M
Ms. Dana Gerner (Age 57)
Chief Financial Officer
Comp: $649k
Mr. Ronnen Armon (Age 61)
Chief Products & Technologies Officer
Comp: $516k
Ms. Lisa Cole (Age 49)
Chief Marketing Officer
Comp: $499k
Mr. Leeor Ben-Peretz (Age 48)
Chief Strategy Officer
Comp: $470k
Mr. Thomas E. Hogan (Age 65)
Executive Chairman
Mr. Arnon Zilberman
Executive Vice President of Information Systems & Operations
Andrew Kramer
Vice President of Investor Relations
Ms. Ayala Berler Shapira (Age 53)
General Counsel & Chief Compliance Officer
Ms. Zohar Tadmor-Eilat (Age 53)
Chief People Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CLBT Stock Analysis - Frequently Asked Questions

Should I buy or sell Cellebrite DI stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellebrite DI in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLBT shares.
View CLBT analyst ratings or view top-rated stocks.
What is Cellebrite DI's stock price target for 2024?: 5 Wall Street research analysts have issued 12 month price targets for Cellebrite DI's shares. Their CLBT share price targets range from $9.00 to $16.00. On average, they expect the company's stock price to reach $12.30 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price.
View analysts price targets for CLBT or view top-rated stocks among Wall Street analysts.
How have CLBT shares performed in 2024?: Cellebrite DI's stock was trading at $8.66 at the start of the year. Since then, CLBT shares have increased by 18.8% and is now trading at $10.29.
View the best growth stocks for 2024 here.
Are investors shorting Cellebrite DI?: Cellebrite DI saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 2,480,000 shares, a drop of 5.3% from the March 15th total of 2,620,000 shares. Based on an average daily volume of 998,300 shares, the short-interest ratio is currently 2.5 days. Currently, 4.5% of the shares of the stock are short sold.
View Cellebrite DI's Short Interest.
When is Cellebrite DI's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 23rd 2024.
View our CLBT earnings forecast.
How can I listen to Cellebrite DI's earnings call?: Cellebrite DI will be holding an earnings conference call on Thursday, May 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Cellebrite DI's earnings last quarter?: Cellebrite DI Ltd. (NASDAQ:CLBT) announced its quarterly earnings data on Thursday, February, 15th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. The business had revenue of $93.01 million for the quarter, compared to analyst estimates of $85.43 million. Cellebrite DI had a positive trailing twelve-month return on equity of 173.14% and a negative net margin of 24.94%.
What ETFs hold Cellebrite DI's stock?: ETFs with the largest weight of Cellebrite DI (NASDAQ:CLBT) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL).Amplify BlueStar Israel Technology ETF (ITEQ).
What guidance has Cellebrite DI issued on next quarter's earnings?: Cellebrite DI issued an update on its first quarter 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $83.0 million-$88.0 million, compared to the consensus revenue estimate of $84.3 million.
Who are Cellebrite DI's major shareholders?: Cellebrite DI's stock is owned by many different retail and institutional investors. Top institutional shareholders include Counterpoint Mutual Funds LLC (0.03%) and Hennessy Advisors Inc. (0.01%).
How do I buy shares of Cellebrite DI?: Shares of CLBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLBT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial